A
Angion Biomedica
Biotech & Life Sciences · Hempstead, United States · Founded 1998
Clinical stage organ restoration biopharmaceutical company focused on renal disease MoreLess
Angion Biomedica Corp is a late-stage clinical company focused on developing small molecules aimed at treating acute organ injury and chronic fibrosis. The company's lead product, ANG-3777, is designed to activate the HGF c-Met pathway, a critical mechanism in organ repair. Angion's primary market includes patients suffering from acute kidney injury related to kidney transplantation and acute lung injury associated with COVID-19 pneumonia. The business model revolves around advancing its clinical trials to achieve regulatory approval, thereby enabling commercialization and partnerships with healthcare providers and pharmaceutical companies. Revenue is generated through the development and potential future sales of its therapeutic products, as well as possible licensing agreements. Angion operates in the biopharmaceutical sector, targeting unmet medical needs in organ injury and fibrosis.
Keywords: small molecules, acute organ injury, chronic fibrosis, kidney injury, lung injury, HGF c-Met pathway, clinical trials, biopharmaceutical, organ repair, therapeutic products.
Company overview
Angion Biomedica company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 1998
- Headquarters
- Hempstead, United States
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 26.7
- Investment activity
- 1 companies · latest Jan 2023
- Capital deployed
- —
- Preferred round
- POST IPO DEBT
Valuation & funding
Angion Biomedica funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2023 | $0 | — | Elicio Therapeutics | ↗ |
| IPO✓Exit | Feb 2021 | $0 | — | Undisclosed | — |
| EARLY VC✓Equity / VC | Jun 2020 | $0 | — | Undisclosed | — |
| GRANT✓Other financing | Apr 2019 | $4.8M | — | US Department of War | — |
| EARLY VC✓Equity / VC | Jul 2018 | $15M | $60M | Undisclosed | — |
| GRANT✓Other financing | Jan 2017 | Small Business Innovation Research | — | ||
| GRANT✓Other financing | Jan 2016 | Small Business Innovation Research | — | ||
| SEED✓Equity / VC | Feb 2015 | Undisclosed | — | ||
| GRANT✓Other financing | Dec 2013 | US National Science Foundation | ↗ | ||
| GRANT✓Other financing | Jan 2013 | Small Business Innovation Research | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Angion Biomedica website traffic
Latest recorded traffic for Angion Biomedica is 4.7K monthly website visits, up 147.4% over the last three months. Angion Biomedica's team declined 14.3% over the past year.
Comparisons
Angion Biomedica compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Angion Biomedica investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Angion Biomedica's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Angion Biomedica has talent and traffic
team presence
In the news
Latest news about Angion Biomedica
Recent press, funding announcements, and product moves mentioning Angion Biomedica — open to read from the original sources.
Market sentiment
What the market is saying about Angion Biomedica
An AI-synthesized read of the highest-engagement posts about Angion Biomedica on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Angion Biomedica’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.